Daniel Kelly
Cardiovascular Disease · Saint Louis, MONPI 1477599512
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $541,335 of the $582,080 with a category attached, or 93.0%. Pfizer accounts for 98.4% of it on its own, with 1 other manufacturer making up the rest. Among cardiovascular disease clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 113 payments — averaging $5151.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$573K
- Amgen$9K
Across 4 payments — averaging $120,060 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$480K
What the payments were for
- Consulting fees$541,33593%
- Speaking & faculty fees$13,5002%
- Travel & lodging$23,1504%
- Food & beverage$4,0961%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$582,080 in reported general payments places this provider in the 95th percentile of 391 cardiovascular disease providers in Missouri.
Other cardiovascular disease in Saint Louis
- Georges ChahoudSaint Louis$937K
- William BowenSaint Louis$726K
- Osler Jay GuzonSaint Louis$211K
- Mohammad TahirSaint Louis$173K
- Robert RifkinSaint Louis$145K
- Martin SchwarzeSaint Louis$113K
- Joshua MitchellSaint Louis$103K
- Zainab MahmoudSaint Louis$100K
- Nizar AssiSaint Louis$81K
- Mustafa HusainiSaint Louis$71K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.